On November 2, the pharmaceutical company “Varus” in cooperation with the Association of General Practitioners and Family Medicine begins a traditional campaign to raise the awareness for the prevention of the development and control of diabetes. With this, Varus joins the global campaign on World Diabetes Day, which the International Diabetes Federation celebrates every year on November 14, this year with the theme “Diabetes – Nurses Make the Difference.”
This year, we put special emphasis on the metabolic syndrome, fatty liver and the connection of these conditions with prediabetes and diabetes, for which there are scientific studies, but also experiences from everyday practice. In this context, the campaign is divided into two topics, according to the above mentioned health conditions.
The campaign this year will take place on the social networks Facebook and Instagram, on the pages “Health Priority – Alarm for Awareness” (https://fbook.cc/3HqA). These are non-commercial sites on which the company at least twice a year conducts campaigns to raise public awareness about certain diseases. This is where informative and educational content related to metabolic syndrome, fatty liver, prediabetes and diabetes will be shared in the context of risk factors, symptoms, prevention and treatment.
In the year marked by the global pandemic of Covid-19, the need to pay attention to other health conditions that should not be neglected is of particular importance. As a pharmaceutical company, we believe that we have a socially responsible role in the community to point out to the public the importance of prevention and timely treatment of health conditions that are increasing every year with more and more worrying statistics. “As authorized representatives of the largest leading science and technology pharmaceutical company, Merck, we are proud to be able to contribute to raising awareness of diabetes as a global problem and an extremely important health issue,” Varus said.
According to the International Diabetes Federation in 2019, 1 of 11 adults (20-79 years) has diabetes, ie the number of adults in the world population with impaired glucose tolerance was 463 million, and by 2030 7% of the world’s population will have impaired glucose tolerance. It is estimated that about 70% of people with untreated IFG (Impaired Fasting Blood Glucose) and / or IGT (Impaired Glucose Tolerance) will develop type 2 diabetes mellitus in the next few years. Prediabetes is also a common condition in the young population of the world. Nearly one-third of patients with prediabetes are between the ages of 20 and 39, and almost half of the total are under the age of 50.
